Converging preclinical studies indicate that pharmacological inhibition of FAAH augments brain AEA levels and elicits anxiolytic-like effects in a CB1 receptor-dependent manner14, 15, 16, 17, 18, providing support for the potential utility of FAAH inhibitors in the treatment of anxiety disorders (for reviews see:19, 20). This evidence concerns the gene FAAH and anxiety disorder.